The type of cancer in which T67 is being tested is often caused by a hepatitis-C infection, which is much more common in Asia.
All I have is my past, but as I have been in counseling (up until two years ago, when it became physically impossible to do so.) to overcome my past-I endured three life threatening health diagnoses-polio, Hepatitis C, and breast cancer-as well as three abusive men-my first husband beat me unmercifully.
Hepatitis -- the most common types being hepatitis A, B and C -- refers to inflammation or viral infections of one's liver.
Estimates say the annual death toll from hepatitis C-related causes in Scotland could be between 100 to 200 by 2015.
It had a big hit with Ribavarin, an anti-viral drug that is packaged with Schering-Plough 's (nyse: SGP - news - people ) hepatitis C drug, PEG-Intron.
Schering-Plough faces legal investigations into its disclosure and pricing practices, a dismal relationship with the Food and Drug Administration and cutthroat competition on its best-selling drug, a treatment for hepatitis C called Peg-Intron.
The drugs, so-called hepatitis C protease inhibitors, represent the first class of agents that directly target the hepatitis C virus.
FORBES: Vertex Edges Merck In First Round of Hepatitis C Fight
Aside from the loss of its prescription allergy franchise, Schering is facing erosion in its top-selling hepatitis C drugs due to the entry of a new competitor from Roche .
Second, Bristol-Myers Squibb stopped a Phase II study of its BMS-094 for hepatitis C because of a serious safety issue.
Cirrhosis caused by chronic hepatitis C or long-term alcohol abuse are the most common reasons for needing a liver transplant.
But with hepatitis C, no-one has been able to pin down how the virus spreads, because cases occur months or years apart.
Liver disease, often the result of co-infection with hepatitis C, is prevalent.
"Working out how many people are likely to be infected by each super-spreader of Hepatitis C, as well as how soon they will be infected, has been a puzzle for over 20 years, " he said.
The evidence they have produced suggests programmes targeting the diagnosis and treatment of hepatitis C in high-risk groups as early as possible would prevent many new infections and associated health care costs many years down the line.
Some doctors had reported positive results using ribavirin, an anti-viral medicine used mostly against hepatitis C, as a treatment for SARS patients who had been worst-hit by the disease in Hong Kong and elsewhere.
Basel, Switzerland-based Roche has started a price war between its hepatitis C drug, Pegasys, and Schering-Plough's Peg-Intron.
The Seattle biotech was the second-best-performing biotechnology stock in August, rising 22% on heightened hopes for the hepatitis C drug it is developing with Bristol-Myers Squibb.
The two-year survival for hepatitis C was also lower for African Americans, although the rate for hepatitis B was similar for this race, white Americans and Hispanics.
More bad news: Mid-stage trials of a new drug for hepatitis C being developed by Wyeth and biotech Viropharma (nasdaq: VPHM - news - people ) were stopped.
The goal, Gilead said in its press release, is to create an all-oral treatment for hepatitis C that would replace the difficult treatment with injected interferon and ribavirin, an antiviral pill, along with the fatigue and other side effects they cause.
FORBES: Gilead Tries To Revive Itself With $11 Billion Purchase Of Pharmasset
Sales of its best-seller, Incivek for hepatitis C, are dropping.
Its next bestseller, PEG-Intron, used to treat hepatitis C, could be challenged soon as well.
Its hepatitis C medicines, Rebetol and Peg-Intron, are facing tough competition from a new entrant from Roche , a Basel, Switzerland-based drug giant.
Also, 24 of 26 patients who received telaprevir in early-stage trials were cured of hepatitis C after six additional months of treatment with interferon and ribavirin.
That would be bad news for hepatitis C players such as Gilead and Bristol-Myers Squibb.
This gives Bristol three different triple-drug approaches to use in treating hepatitis C.
Doctors told her she could never take interferon again-a big problem because the main hepatitis C regimens all use this protein.
This year, Roche has eaten Schering-Plough 's (nyse: SGP - news - people ) lunch in the hepatitis C market.
It helps Bristol-Myers Squibb play in the emerging hepatitis C market by giving the company full control of the drug the two firms were developing together.
In justifying his strong buy rating on the company, Carl Byrns at Dain Rauscher Wessels points to an anti-viral drug: Peg-intron plus ribavirin combination therapy for Hepatitis C.
应用推荐